BlueRun Ventures Continues to Double Down: Morelly Bio Closes New Nine-Figure RMB Funding Round | BlueRun Portfolio

Shanghai Moyoung Biotechnology recently announced the successful completion of a new funding round worth several hundred million RMB, with BlueRun Ventures participating as an investor. This round provides a significant boost to Moyoung's continued deep dive into regenerative biomaterials, accelerating the commercial rollout of core products including the Aphranel™ "Magic CC Needle," while providing solid support across production, sales, and brand building — supplying strong financial backing for the company's R&D innovation, market expansion, and global footprint.

The proceeds will primarily go toward further expanding the marketing team, increasing global market coverage, and simultaneously accelerating next-generation product development. The funding will advance Moyoung's industrial layout in regenerative medical aesthetics and help it sprint toward its goal of becoming a "leading enterprise in regenerative medical aesthetics."

The BlueRun Ventures team commented: "The medical aesthetics industry is undergoing profound transformation, gradually shifting from a sales-driven model to one centered on differentiated product value. The market continues to call for breakthrough innovations with transformative efficacy. Notably, China's medical aesthetics industry has evolved from technology follower to global R&D leader. Leveraging its systematic R&D platform capabilities, Moyoung has demonstrated its power to tackle technical bottlenecks through both its existing pipeline and forward-looking product portfolio. We are honored to participate in this round and look forward to helping the company push technological boundaries and jointly lead the industry's innovative future."

Moyoung will also use this funding as a springboard to uphold its mission of "returning medical aesthetics to the essence of medicine," continuing to use innovative technology as its engine to drive product applications, providing doctors and patients with more rigorous and professional services, contributing more to "New China Smart Manufacturing" in China's plastic and reconstructive surgery field, and offering more competitive Chinese solutions to the global medical aesthetics market.

Founded in 2018, Shanghai Moyoung Biotechnology holds fully independent patents and is an internationally leading high-tech enterprise recognized as a "little giant" specialist. Its Aphranel™ brand represents China's independently developed premium injectable hydroxyapatite calcium microsphere facial filler — the first product in China to receive NMPA Class III medical device registration certification for medical aesthetics indications. It has also secured multiple international certifications including EU MD, five-country MDSAP, and Mexico COFEPRIS product registration. Moreover, it is one of the world's first leading medical aesthetics brands to achieve precise control of CaHA microsphere particle size, pore size, and degradation rate, with fully independent R&D, production, and sales. Moyoung's patented CaHA material, prized for its safety, complete biodegradability, and natural results, has earned the trust and appreciation of experts and patients worldwide. Upholding the mission of "returning medical aesthetics to the essence of medicine," the company consistently uses innovative technology to drive product applications, providing doctors and consumers with safe, high-quality products and rigorous, professional service.

Regarding the addition of new shareholders in this round, Moyoung Chairman Lin Guangming stated: "The support from our new shareholders represents high recognition of Moyoung's achievements in deep cultivation of regenerative biomaterials, and even more so, firm confidence in the future potential of the medical aesthetics industry. These investors possess deep resource accumulation and rich successful experience in the healthcare sector. They bring not only strong financial support but also precise industry insight and extensive resource networks that will inject fresh momentum into our product iteration, market expansion, and brand upgrading."

"Through this partnership, Moyoung will accelerate the global commercial layout of core products including the Aphranel™ 'Magic CC Needle,' further increasing market penetration in regenerative medical aesthetics. Meanwhile, with the support of our new shareholders, we can more efficiently advance next-generation product development and consolidate our global leading position in precise CaHA material control technology. Going forward, we will work hand-in-hand with all shareholders, guided by our mission of 'returning medical aesthetics to the essence of medicine,' continuously driving industrial upgrading through innovative technology — not only contributing 'New China Smart Manufacturing' strength to China's medical aesthetics market, but also exporting competitive Chinese solutions globally. Together we will seize new opportunities in the regenerative medical aesthetics industry and sprint full speed toward our goal of becoming a 'leading enterprise in regenerative medical aesthetics.'"

---

SinoBrain Completes Series A+ Funding | BlueRun Family Zealand Pharma Completes $40 Million Series A+ to Accelerate Myeloid Cell Engager Pipeline | BlueRun Family

BlueRun Ventures Leads $42 Million Series A for AllinkBio | BlueRun Family